What’s the current market cap for Kyverna Therapeutics stock?

Kyverna Therapeutics (KYTX) has a market cap of $488m as of June 20, 2026.

What is the P/E ratio for Kyverna Therapeutics stock?

The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of June 20, 2026.

Does Kyverna Therapeutics stock pay dividends?

No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of June 20, 2026.

When is the next Kyverna Therapeutics dividend payment date?

Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Kyverna Therapeutics?

Kyverna Therapeutics (KYTX) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Kyverna Therapeutics stock | $KYTX Share Price

13:30

15:10

16:45

18:25

20:00

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Ticker

$KYTX

Sector

Health

Primary listing

NASDAQ

Employees

129

Headquarters

Emeryville, United States

Website

kyvernatx.com

KYTX Metrics

BasicAdvanced

$488m

-$3.23

1.96

What the Analysts think about KYTX

Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.

Bulls say / Bears say

Kyverna’s miv-cel (KYV-101) achieved statistically significant clinical benefit across all primary and secondary endpoints in its registrational KYSA-8 Phase 2 trial for stiff person syndrome—with no high-grade CRS or ICANS observed—paving the way for a planned BLA submission in H1 2026 (StockTitan).

Kyverna enrolled the first patient in its FDA-aligned registrational Phase 3 trial of miv-cel in generalized myasthenia gravis in December 2025, expanding its pipeline into multiple neuroimmunology indications (StockTitan).

The company reported $279.3 million in cash, cash equivalents and marketable securities as of December 31, 2025, extending its financial runway into 2028 to fund SPS BLA filing, commercial launch and Phase 3 gMG trial (StockTitan).

Kyverna reported a net loss of $39.7 million (–$0.66 per share) for Q1 2026, underscoring persistent operating deficits as it transitions toward commercial readiness (Reuters).

Cash reserves declined from $279.3 million at December 31, 2025 to $236.4 million at March 31, 2026, reducing runway to approximately one year and increasing the risk of future equity dilution (Company 10-Q).

Full-year 2025 R&D expenses rose to $133.7 million from $112.5 million in 2024 (and G&A rose to $36.1 million from $30.1 million), driving a wider annual net loss of $161.3 million versus $127.5 million the prior year (StockTitan).

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

KYTX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

KYTX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Kyverna reported a net loss of $39.7 million (–$0.66 per share) for Q1 2026, underscoring persistent operating deficits as it transitions toward commercial readiness (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

About Kyverna Therapeutics

Ticker

Employees

KYTX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about KYTX

Analyst Ratings

Bulls say / Bears say

KYTX Financial Performance

Income Statement

KYTX Earnings Performance

Earnings per share (EPS)

Buy $KYTX

Lightyear

Legal

Work with us

Bulls say / Bears say

Kyverna Therapeutics/$KYTX

About Kyverna Therapeutics

Ticker

Employees

KYTX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about KYTX

Analyst Ratings

Bulls say / Bears say

KYTX Financial Performance

Income Statement

KYTX Earnings Performance

Earnings per share (EPS)

What’s the current market cap for Kyverna Therapeutics stock?

What is the P/E ratio for Kyverna Therapeutics stock?

Does Kyverna Therapeutics stock pay dividends?

When is the next Kyverna Therapeutics dividend payment date?

What is the beta indicator for Kyverna Therapeutics?

Bulls say / Bears say